EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY 4.0

Real-Life Outcomes of First-Line Palliative Chemoimmunotherapy in Oesophago-Gastric Cancers: A Multi-Centre Retrospective Cohort Study

James Birch-Ford iD, Ben Crosby, Grace Langford iD, Alexandra Johnson, Helen Wong iD, Shobha Silva, Amy Jackson, Roopa Kurup, Joachim Chan iD, Alia Alchawaf, Tom Crosby

Cancers · 09.05.2026 · 18 (10) · 1522

DOI: 10.3390/cancers18101522 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Cancers, online erschienen am 09.05.2026. Verfasst von James Birch-Ford und 10 weiteren Autor:innen. Beteiligte Einrichtung: Whiston Hospital, Mersey and West Lancashire Teaching Hospitals NHS Trust, Prescot L35 5DR, UK. Die Arbeit nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Chemoimmunotherapy has improved survival compared with chemotherapy alone in phase III trials of advanced oesophago-gastric (OG) cancers; however, real-world UK data under National Institute for Health and Care Excellence (NICE) eligibility criteria remain limited. This study evaluated the effectiveness and safety of first-line pembrolizumab- or nivolumab-based chemoimmunotherapy in routine clinical practice.

Methods

We conducted a retrospective, multi-centre cohort study of patients with unresectable or metastatic oesophageal, gastro-oesophageal junction, or gastric cancers treated with first-line chemoimmunotherapy at two UK tertiary centres between April 2021 and July 2024. Clinical, laboratory, radiological, and toxicity data were collected. Radiological outcomes were based on retrospective review of reports issued by consultant radiologists during routine clinical care. Overall survival (OS) and progression-free survival (PFS) were analysed using the Kaplan–Meier method, with exploratory analyses of prognostic factors.

Results

Seventy-six patients were included (59.2% ≥ 65 years; 81.6% adenocarcinoma; 71.1% metastatic). At a median follow-up of 11 months, 46 deaths had occurred. Median OS was 16.0 months (95% CI: 11.0–20.9), and median PFS was 8.0 months (95% CI: 6.8–9.2). Disease control occurred in 80.3% of patients and was associated with improved OS compared with progressive disease (17.0 vs. 4.0 months; p < 0.001). Survival outcomes did not differ significantly by tumour site, histology, or immunotherapy agent. Immunotherapy-related adverse events occurred in 31 patients (40.8%), with grade ≥ 3 toxicities in 13.2% and two treatment-related deaths. Exploratory analyses suggested potential associations between survival and baseline lymphocyte count and neutrophil–lymphocyte ratio, although these did not reach statistical significance.

Conclusions

In this real-world UK multi-centre cohort, first-line chemoimmunotherapy demonstrated survival outcomes comparable to pivotal clinical trials, with manageable toxicity. These findings support the use of chemoimmunotherapy in routine practice. Prospective collaborative studies incorporating robust biomarker evaluation are warranted to optimise patient selection and better define predictors of response and toxicity.

Schlagwörter

Stichwörter der Autor:innen

chemoimmunotherapygastric cancergastro-oesophageal junction cancergastrointestinal cancersimmunotherapy toxicitynivolumaboesophageal canceroesophago-gastric cancerspembrolizumab

Autor:innen und Institutionen

  • Whiston Hospital, Mersey and West Lancashire Teaching Hospitals NHS Trust, Prescot L35 5DR, UK.
  • The Clatterbridge Cancer Centre, Clatterbridge Cancer Centre NHS Foundation Trust, Liverpool L7 8YA, UK.
  • Velindre Cancer Centre, Velindre University NHS Trust, Cardiff CF15 7QZ, UK.

ORCID-Profile: James Birch-Ford, Grace Langford, Helen Wong, Joachim Chan

Zitieren

APA

Birch-Ford, J., Crosby, B., Langford, G., Johnson, A., Wong, H., Silva, S., Jackson, A., Kurup, R., Chan, J., Alchawaf, A., & Crosby, T. (2026). Real-Life Outcomes of First-Line Palliative Chemoimmunotherapy in Oesophago-Gastric Cancers: A Multi-Centre Retrospective Cohort Study. Cancers, 18(10), 1522. https://doi.org/10.3390/cancers18101522

Vancouver

Birch-Ford J, Crosby B, Langford G, Johnson A, Wong H, Silva S, et al. Real-Life Outcomes of First-Line Palliative Chemoimmunotherapy in Oesophago-Gastric Cancers: A Multi-Centre Retrospective Cohort Study. Cancers. 2026;18(10):1522. doi:10.3390/cancers18101522

BibTeX
@article{BirchFord2026,
  author = {Birch-Ford, James and Crosby, Ben and Langford, Grace and Johnson, Alexandra and Wong, Helen and Silva, Shobha and Jackson, Amy and Kurup, Roopa and Chan, Joachim and Alchawaf, Alia and Crosby, Tom},
  title = {Real-Life Outcomes of First-Line Palliative Chemoimmunotherapy in Oesophago-Gastric Cancers: A Multi-Centre Retrospective Cohort Study},
  journal = {Cancers},
  year = {2026},
  volume = {18},
  number = {10},
  pages = {1522},
  doi = {10.3390/cancers18101522}
}
Kostenlos starten →